Karolinska Development’s portfolio company Modus Therapeutics presents positive results from a clinical trial of sevuparin bit.ly/3Y6c8kh

Karolinska Development’s portfolio company Aprea Therapeutics secures funding of USD 5.5 million bit.ly/3krQyJe

Karolinska Development’s portfolio company SVF Vaccines initiates clinical phase 1 study of its universal Covid-19 vaccine bit.ly/41zTjbO

Karolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal infection bit.ly/3T9fOkg

Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01 bit.ly/4298tVT

Karolinska Development Annual Report 2022 published bit.ly/3FMmU8K

Karolinska Development’s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone bit.ly/40Ds7ru

Notice of Annual General Meeting in Karolinska Development AB (publ) bit.ly/3KP0fM1

Karolinska Development’s portfolio company AnaCardio recruits first patient to a clinical trial of its drug candidate AC01 bit.ly/3o8CXb0

Karolinska Development’s portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis bit.ly/3MQpAGY

Interim Report - January-March 2023 bit.ly/41KT39P

Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia bit.ly/3HZu2jq

Karolinska Development’s Annual General Meeting 2023 bit.ly/3M5PHHT

Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce neuroinflammation bit.ly/3NgQ1Fm

Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease bit.ly/43bIE6Q

Interim Report - January-June 2023 bit.ly/3KWKhim

Karolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication bit.ly/3PraxDe

Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company bit.ly/3rzg3vp

Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047 bit.ly/3ZBcSQp

Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047 bit.ly/4680mKO